CAR T-cell therapy after CD34 selection for CD19 lymphoma or CLL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1/2 study tests a customized type of immune cell treatment (CD19 CAR T-cells) for people with certain relapsed or hard-to-treat lymphomas or CLL/SLL. It aims to improve control of disease by targeting the CD19 marker on cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- Your cancer is one of these CD19-positive blood cancers, or mantle cell lymphoma, or CLL/SLL.
- Your disease has come back or is not responding after enough prior treatments (details depend on lymphoma type).
- You have measurable disease on scans (or, for CLL only, enough disease in bone marrow).
- Your blood counts and organ tests are high enough (platelets, infection-fighting cells, liver, kidneys, oxygen).
- If you had CD19-targeted treatment before, your cancer tissue must still show CD19 (from a new biopsy after that treatment).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a personalized form of immune therapy called CAR T cells that are designed to recognize CD19, a marker on certain B-cell cancers. It may help people with difficult-to-treat (recurrent or relapsed) B-cell lymphoma or leukemia (ALL/CLL).
This trial tests a type of personalized immune treatment (CD19 CAR T cells made from your T cells) for adults (and children with ALL) whose CD19-positive blood cancer has come back or didn’t respond. It may help your immune system recognize and attack cancer cells that still have CD19.
This trial tests a new type of CAR T-cell therapy that targets three proteins (CD19, CD20, and CD22) on lymphoma cells. It's for people with B-cell lymphomas that have come back or not responded to at least two prior treatments.
This trial tests a personalized cancer treatment called CAR-T therapy. It uses your own immune cells, which are modified in a lab to fight your specific type of blood cancer, and then given back to you. The goal is to see if this treatment is safe and feasible when produced locally.
This Phase 2 trial tests a locally manufactured CAR T-cell treatment for certain B-cell lymphomas and B-ALL that have limited treatment options left. It may help your immune system attack cancer cells that carry the CD19 marker, potentially as a bridge to transplant for some patients.
This Phase 1 study tests lab-made immune cells (CAR T-cells) that target CD19, CD20, and/or CD22 in people with certain relapsed or refractory B-cell cancers. It may help by attacking cancer cells that still carry these targets, but eligibility is very specific and includes prior treatments and health/lab requirements.
Hear when a new B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.